Allovir Inc (ALVR)

NASDAQ
8.26
0.00(0.00%)
  • Volume:
    169,750
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    7.92 - 8.46

ALVR Overview

Prev. Close
8.26
Day's Range
7.92-8.46
Revenue
-
Open
8.05
52 wk Range
7.48-47
EPS
-2.23
Volume
169,750
Market Cap
512.24M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
222,649
P/E Ratio
-
Beta
-
1-Year Change
-80.65%
Shares Outstanding
62,014,196
Next Earnings Date
Feb 10, 2022
What is your sentiment on Allovir Inc?
or
Market is currently closed. Voting is open during market hours.

Allovir Inc Company Profile

Employees
110

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellNeutralStrong SellStrong Sell
Technical IndicatorsStrong SellStrong BuyStrong BuyStrong SellStrong Sell
SummarySellNeutralBuyStrong SellStrong Sell
  • Insane!
    0
    • Maybe we have bottomed now?
      0
    • Maybe we have bottomed now?
      0
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.